NO20062694L - Inhibitor av mutant form av KIT - Google Patents

Inhibitor av mutant form av KIT

Info

Publication number
NO20062694L
NO20062694L NO20062694A NO20062694A NO20062694L NO 20062694 L NO20062694 L NO 20062694L NO 20062694 A NO20062694 A NO 20062694A NO 20062694 A NO20062694 A NO 20062694A NO 20062694 L NO20062694 L NO 20062694L
Authority
NO
Norway
Prior art keywords
kit
inhibitor
mutant form
mutant
administered
Prior art date
Application number
NO20062694A
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20062694L publication Critical patent/NO20062694L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Den foreliggende oppfinnelse vedrører behandling av KIT avhengige sykdommer som er karakterisert ved en mutant form av KIT hvorved KIT mutanten er identifisert og en passende inhibitor av KIT mutanten valgt fra midostaurin, vatalanib og forbindelse A er administrert.
NO20062694A 2003-11-18 2006-06-12 Inhibitor av mutant form av KIT NO20062694L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18
PCT/EP2004/013045 WO2005049032A1 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit

Publications (1)

Publication Number Publication Date
NO20062694L true NO20062694L (no) 2006-06-12

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062694A NO20062694L (no) 2003-11-18 2006-06-12 Inhibitor av mutant form av KIT

Country Status (27)

Country Link
US (3) US8017621B2 (no)
EP (2) EP1686997B1 (no)
JP (3) JP4762150B2 (no)
KR (1) KR101153647B1 (no)
CN (3) CN102274230B (no)
AT (1) ATE428426T1 (no)
AU (1) AU2004290902B2 (no)
BR (1) BRPI0416680A (no)
CA (1) CA2546189C (no)
CY (1) CY1110354T1 (no)
DE (1) DE602004020654D1 (no)
DK (1) DK1686997T3 (no)
ES (1) ES2324917T3 (no)
HR (1) HRP20090390T1 (no)
IL (2) IL175578A (no)
MA (1) MA28176A1 (no)
MX (1) MXPA06005598A (no)
NO (1) NO20062694L (no)
NZ (1) NZ547195A (no)
PL (1) PL1686997T3 (no)
PT (1) PT1686997E (no)
RU (2) RU2362562C2 (no)
SG (1) SG139747A1 (no)
SI (1) SI1686997T1 (no)
TN (1) TNSN06138A1 (no)
WO (1) WO2005049032A1 (no)
ZA (1) ZA200603905B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
RU2362562C2 (ru) 2003-11-18 2009-07-27 Новартис Аг Ингибиторы мутантной формы киназы kit
MX2007002415A (es) * 2004-08-31 2007-04-23 Novartis Ag Uso de midostaurina para el tratamiento de tumores estromales gastrointestinales.
MX2007013741A (es) 2005-05-02 2008-01-21 Novartis Ag Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistemica.
MX2007013738A (es) * 2005-05-02 2008-01-24 Novartis Ag Derivados de pirimidilaminobenzamida para sindrome hipereosinofilico.
CA2615598C (en) * 2005-07-20 2014-04-15 Peter Valent Compositions for treatment of systemic mastocytosis
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
ES2549327T3 (es) * 2005-12-06 2015-10-27 Novartis Ag Derivados de pirimidilaminobenzamida para el tratamiento de la neurofibromatosis
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
CN101951910B (zh) * 2008-01-23 2013-07-17 诺瓦提斯公司 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途
JP6992960B2 (ja) 2013-12-02 2022-02-03 ベルゲンビオ アーエスアー キナーゼ阻害剤の用途
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (zh) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
US20220010382A1 (en) * 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (no) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
PL313973A1 (en) * 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
WO1998055152A1 (en) 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
BR9815288A (pt) 1997-11-13 2001-02-13 Histatek Llc Composição farmacêutica, processos para inibir a desgranulação de mastócitos, para tratar asma em um paciente, para tratar inflamação em um paciente, para inibir a liberação de citocinas em um paciente, para inibir a liberação de histaminas em um paciente, para inibir a liberação de leucotrienos em um paciente, para reduzir a adesão, migração e agregação de linfócitos, eosinófilos e neutrófilos para um sìtio de inflamação em um paciente, para reduzir a produção de anticorpos ige no sìtio de inflamação em um paciente, para inibir a permeabilidade vascular aumentada no sìtio de inflamação em um paciente, e, para tratar inflamação crÈnica em um paciente.
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
US20040157855A1 (en) * 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
JP2005503361A (ja) 2001-06-29 2005-02-03 アブ サイエンス 肥満細胞症治療のための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
CN1625602A (zh) 2002-03-13 2005-06-08 霍夫曼-拉罗奇有限公司 选择药物敏感性决定因子的方法和利用所选择的因子预测药物敏感性的方法
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
CA2538523A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
RU2362562C2 (ru) 2003-11-18 2009-07-27 Новартис Аг Ингибиторы мутантной формы киназы kit
MX2007013741A (es) 2005-05-02 2008-01-21 Novartis Ag Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistemica.
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
HRP20090390T1 (hr) 2009-08-31
JP4762150B2 (ja) 2011-08-31
JP2007511567A (ja) 2007-05-10
MXPA06005598A (es) 2006-08-11
KR20060101761A (ko) 2006-09-26
CN102274230B (zh) 2015-07-01
AU2004290902A1 (en) 2005-06-02
SG139747A1 (en) 2008-02-29
WO2005049032A1 (en) 2005-06-02
IL175578A0 (en) 2008-04-13
CA2546189A1 (en) 2005-06-02
KR101153647B1 (ko) 2012-06-18
CY1110354T1 (el) 2015-04-29
ES2324917T3 (es) 2009-08-19
RU2009110449A (ru) 2010-09-27
EP1686997B1 (en) 2009-04-15
JP2011121973A (ja) 2011-06-23
IL229124A0 (en) 2013-12-31
RU2362562C2 (ru) 2009-07-27
JP2013241438A (ja) 2013-12-05
US20120157441A1 (en) 2012-06-21
IL175578A (en) 2013-10-31
MA28176A1 (fr) 2006-09-01
SI1686997T1 (sl) 2009-08-31
RU2006121447A (ru) 2008-01-10
US8124611B2 (en) 2012-02-28
ZA200603905B (en) 2008-11-26
US20070213317A1 (en) 2007-09-13
EP1686997A1 (en) 2006-08-09
CA2546189C (en) 2013-04-23
US8017621B2 (en) 2011-09-13
CN1882344A (zh) 2006-12-20
EP1917965A1 (en) 2008-05-07
PL1686997T3 (pl) 2009-09-30
NZ547195A (en) 2010-06-25
PT1686997E (pt) 2009-07-17
DE602004020654D1 (de) 2009-05-28
DK1686997T3 (da) 2009-07-27
US20100179179A1 (en) 2010-07-15
CN101693031A (zh) 2010-04-14
AU2004290902B2 (en) 2008-09-25
ATE428426T1 (de) 2009-05-15
RU2405553C1 (ru) 2010-12-10
CN102274230A (zh) 2011-12-14
HK1093680A1 (en) 2007-03-09
TNSN06138A1 (fr) 2007-11-15
BRPI0416680A (pt) 2007-02-13

Similar Documents

Publication Publication Date Title
IL229124A0 (en) Inhibitors with a mutant form of kit
NO20034056D0 (no) Proliferative sykdommer
ECSP045429A (es) Combinacion de compuestos organicos
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE60329515D1 (de) Analoga und prodrugs von buprenorphin
ATE510534T1 (de) Naltrexonhydrochlorid-zusammensetzungen
NO20044402L (no) Kombinasjonsbehandling av kemokine-medierte sykdommer
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BR0307998A (pt) Hidroxietilaminas substituìdas
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
TW200603823A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
EA200501584A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
BR0312446A (pt) 2-heteroaril carboxamidas
ECSP055844A (es) Nuevos compuestos triciclicos
SE0004827D0 (sv) Therapeutic compounds
DK1601352T3 (da) Kombineret anvendelse af et fibrat og orlistat til behandling af fedme
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
ATE426613T1 (de) Cc-chemokin-antagonisten
HN2003000228A (es) Derivados benzufurano y benzotiofeno utiles en el tratamiento de desordenes hiper - proliferativos
NO20022883A (no) Fremgangsmåte for behandling av trevirke
UA2986U (uk) Спосіб лікування розсіяного склерозу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application